Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of naldemedine for opioid-induced constipation in cancer patients
jRCT2080222291Phase 3
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in opioid-induced constipation (OIC) comparing Naldemedine with Placebo (2 arms).
02
Drugs
naldemedine
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on jRCT2080222291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222291.